Bronchial artery embolisation in management of hemoptysis – A retrospective analysis in a tertiary university hospital

Dabó, Hans; Gomes, Ricardo Zanetti; Marinho, Anabela; Madureira, Miguel; Paquete, Joaquim; Morgado, Paulo Vilares

doi:10.1016/j.rppnen.2015.09.001

Cited by 24 publications

(37 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The most common complications after BAE included transient chest/ back pain and dysphagia which were reported in 1.4%-34.5% and 0.7%-30%, respectively (6,9,11,13,15,16,18,(22)(23)(24)(25)(26)(27). These figures were lower than those reported previously in older reviews and in studies with less than 50 patients (2,3).…”

Section: Complicationsmentioning

confidence: 73%

“…Certain angiographic features such as: a) presence of nonbronchial systemic collaterals, b) bronchopulmonary shunting, and c) incomplete initial embolization were significantly associated with higher recurrence rates (5,12,13,22,23). While a higher recurrence rate has been reported previously in patients with pleural thickening more than 10 mm as it is associated with recruitment of nonbronchial systemic collaterals (30,31), none of the studies in this review observed a significant association between pleural thickening and recurrence.…”

Section: Outcomes Of Baementioning

confidence: 99%

“…We also excluded five studies whose full-texts were not available despite our best efforts. Finally, there were 22 studies (5)(6)(7)(8)(9)(10)(11)(12)(13)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27) meeting the selection criteria for this systematic review. The search strategy is schematized in Fig.…”

Section: Final Study Selectionmentioning

confidence: 99%

“…Furthermore, some authors emphasized that even a small volume of hemoptysis could flood the airspaces in diseased lungs, cause asphyxiation and thus be potentially life-threatening (27). Few studies, instead of grading severity of hemoptysis, described whether BAE was performed in acute massive hemoptysis under emergent conditions or was performed electively for chronic recurrent hemoptysis (13,22). Also, the amount of hemoptysis was not quantified in two studies (11,20).…”

Section: Grades Of Hemoptysismentioning

confidence: 99%

“…Coils provide more proximal occlusion compared with PVA, gelatin sponge, and liquid embolizing agents, and thus were used for embolization of pseudoaneurysms, arteriovenous malformations and nonbronchial systemic collaterals in combination with other embolizing agents (7,9,11,13,20,22,(25)(26)(27).…”

Section: -27) This Was In Contrast Tomentioning

confidence: 99%

See 4 more Smart Citations

Bronchial artery embolization in hemoptysis: a systematic review

Panda¹,

Bhalla²,

Goyal³

2017

Diagn Interv Radiol

208

231

View full text Add to dashboard Cite

Section: Complicationsmentioning

confidence: 73%

Section: Outcomes Of Baementioning

confidence: 99%

Section: Final Study Selectionmentioning

confidence: 99%

Section: Grades Of Hemoptysismentioning

confidence: 99%

Section: -27) This Was In Contrast Tomentioning

confidence: 99%

See 3 more Smart Citations

Bronchial artery embolization in hemoptysis: a systematic review

Panda¹,

Bhalla²,

Goyal³

2017

Diagn Interv Radiol

208

231

View full text Add to dashboard Cite

The Management of Chronic Pulmonary Aspergillosis: The UK National Aspergillosis Centre Approach

Maghrabi

Denning

2017

Curr Fungal Infect Rep

View full text Add to dashboard Cite

Purpose of ReviewChronic pulmonary aspergillosis (CPA) is a serious long-term fungal disease of the lung with a worldwide prevalence. Treatment of CPA is not straightforward given the often-multiple associated co-morbidities, complex clinical picture, drug interactions, toxicities and intolerances.Recent FindingsFirst line treatment is oral itraconazole or voriconazole. In the event of intolerance or toxicity, patients may be swapped from itraconazole to voriconazole or vice versa. In the event of resistance or further intolerance, third line treatment with posaconazole could be initiated. In those with pan-azole resistance, short-term courses of intravenous liposomal amphotericin B or micafungin are fourth line therapy, keeping in mind the nephrotoxic effects of amphotericin B.SummaryThe available evidence for current treatments in CPA is limited and based mostly on retrospective cohort studies. There is a real need to raise awareness of this devastating disease to enable early treatment as well as prospective drug trials and studies to identify potential patient factors that correlate with progression, severity and overall outcomes in order to target future therapies.

show abstract